One dose of protein-targeting CAR-T cells shrinks solid tumors in preclinical tests

CAR-T cell therapies have fundamentally transformed the treatment of several blood and lymph node cancers. However, their use in solid tumors such as liver, breast or lung cancer has so far been significantly more difficult. This is due, among other things, to the lack of suitable target structures on the cancer cells. Cancer immunotherapies typically target features that are characteristic of a tumor and that, in some cases, directly drive its growth. However, such mutations are not always present or cannot be exploited therapeutically.

Read it at Medical Xpress ↗

← Front page